On April 7, 2022 Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, reported a Phase I clinical trial cancer patient who continues to benefit from continuous zabadinostat therapy for over 2 years (Press release, Celleron, APR 7, 2022, View Source [SID1234611578]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CXD101-0901 is a clinical trial sponsored by Oxford University Hospitals NHS Foundation Trust, with support from Celleron Therapeutics. It is an open-label, Phase I study in patients with various advanced tumours where zabadinostat (formerly CXD101) is administered orally, twice daily, for 5 days, repeated every 3 weeks. The study began with a dose escalation phase to determine the maximum tolerated dose. Dose expansion was then opened at a recommended dose of 40mg daily. A total of 17 patients were treated in the dose expansion, which was closed to enrolment in 2019.

As of March 2022, one patient continues to receive zabadinostat monotherapy, having started treatment in December 2019. This patient has tolerated the drug well, experiencing few drug-related side effects with over 2 years of therapy. In terms of clinical response, the patient’s tumour has been effectively controlled during this extended period of time.

Dr Graham Collins, Principal Investigator and Haematology Consultant at the Oxford University Hospitals, commented:

"It’s really gratifying to have a patient with high-risk cancer responding so well for so long to an oral and well tolerated treatment."

Professor David Kerr, Chief Medical Officer of Celleron Therapeutics commented:

"We are excited by this encouraging long-term response to monotherapy, which adds to the continuing evidence that zabadinostat is a clinically viable drug with wide utility in clinically unmet disease. It is of interest that this subject has been able to tolerate dosing for more than 2 years, without experiencing any serious adverse drug reactions. We expect to further develop our understanding of this response with our upcoming large-scale clinical trials".